Advokatfirman Lindahl has advised Intervacc AB on its listing on Nasdag First North and the issue of units directed to the public in Sweden and to institutional investors, which is carried out as a part of the listing. A prospectus in respect of the listing and the new issue has been made public on 23 February 2017, and the preliminary date for first day of trading on Nadsaq First North is 7 April 2017.
Intervacc AB is a company in the biotechnology sector. The company's main area is to develop modern subunit vaccines for economically important bacterial infections, primarily in animal health care. The company's vaccine candidates are based on many years of research at the Karolinska Institute and the Swedish University of Agricultural Sciences that laid the foundation for the technology platform that forms the basis for the Company's research and development.
Advokatfirman Lindahl assisted Intervacc in the listing and the new issue through a team lead by Per Hedman (Life sciences) and Annika Andersson (Capital Markets and Public M&A), together with Olivia Toftgård, Anton Knifström and Oscar Lunde (Capital Markets and Public M&A), Erik Sundgren and Natalie Tell (M&A), Annie Kabala (Intellectual Property) and Anna Romell Stenmark and Therese Norenäs (Tax).
